Open-Label, Single-Sequence Study to Evaluate the Effects of Darunavir/Ritonavir and/or Etravirine on the Pharmacokinetics of GSK3640254 and the Effects of GSK3640254 on the Pharmacokinetics of Darunavir/Ritonavir and/or Etravirine in Heathy Adults
Latest Information Update: 23 Aug 2023
At a glance
- Drugs Fipravirimat (Primary) ; Darunavir/ritonavir; Etravirine
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
Most Recent Events
- 11 Oct 2021 Status changed from active, no longer recruiting to completed.
- 04 Oct 2021 Planned End Date changed from 1 Oct 2021 to 4 Oct 2021.
- 04 Oct 2021 Planned primary completion date changed from 1 Oct 2021 to 4 Oct 2021.